Drug intelligence / Profile preview

NVP-1705

Development stage: Phase 1
Lead developer: Navipharm
Modality: Small Molecules
Administration: Oral

Overview

NVP-1705 is a small molecule drug developed by Navipharm for the treatment of cardiovascular diseases. Its precise mechanism of action and molecular target have not been publicly disclosed. The compound has undergone Phase 1 clinical evaluation to assess its pharmacokinetics and safety in healthy subjects, including comparison with a related compound, NVP-1705-R. As of March 2025, its highest global R&D status is listed as "Discovery," indicating early-stage development focused on cardiovascular therapeutic indications[1][2][4].

Beyond the preview

Go deeper on NVP-1705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-1705.

Explore the full profile